Enter multiple symbols separated by commas

ImClone Shares Plummet After Erbitux Fails in Cancer Study

ImClone Systems said that a late-stage trial of its cancer drug Erbitux failed to improve overall survival in patients with pancreatic cancer. Imclone shares fell as much as 11% to $37.58 following the announcment.

The New York-based biotechnology company and its partner Bristol-Myers Squibb said Erbitux in combination with chemotherapy did not meet the main goal of the trial, which compared patients with locally advanced unresectable or metastatic pancreatic cancer who took Erbitux plus chemotherapy with patients who took chemotherapy alone.

Erbitux is currently approved to treat colorectal cancer and head and neck cancer.

The 700-patient trial was conducted by the Southwest Oncology Group.

Contact U.S. News


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

  • Dani Mathers, the 2015 Playmate of the Year, poses during a luncheon on the garden grounds of the Playboy Mansion in Los Angeles, May 14, 2015.

    Playboy on Thursday launched its completely safe-for-work mobile app Playboy NOW, part of a strategy to make more mainstream content.

  • Li Hejun, Hanergy Holding Group

    In the history of sudden wealth loss, Li Hejun may have set a new record.

  • Marc Cuban

    Ask Mark Cuban what the next big thing in technology is, you'll get an answer straight out of a science fiction film.

U.S. Video

  • America's most diverse cities

    These towns are the best for racial, income and educational diversity.

  • Cuba/US in diplomatic talks

    CNBC's Michelle Caruso-Cabrera, has an update on talks between the U.S. and Cuba to establish diplomatic ties, as the countries attempt to overcome several major hurdles.

  • Can GAP get its mojo back?

    Dorothy Lakner, Topeka Capital Markets, provides perspective on what's hurting the apparel retailer and why things are working at Old Navy.